|
Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors. |
| |
|
Employment - Genentech/Roche; ORIC Pharmaceuticals |
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - ORIC Pharmaceuticals (Inst) |
| |
|
Employment - ORIC Pharmaceuticals |
Stock and Other Ownership Interests - ORIC Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - ORIC Pharmaceuticals (Inst) |
| |
|
Employment - ORIC Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - ORIC Pharmaceuticals (Inst) |
| |
|
Employment - ORIC Pharmaceuticals; Zai Lab |
Stock and Other Ownership Interests - ORIC Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - ORIC Pharmaceuticals; ORIC Pharmaceuticals (Inst) |
| |
|
Employment - ORIC Pharmaceuticals |
Stock and Other Ownership Interests - ORIC Pharmaceuticals |
| |
|
No Relationships to Disclose |
| |
|
Employment - ACEA Therapeutics; ORIC Pharmaceuticals |
Stock and Other Ownership Interests - ACEA Therapeutics; ORIC Pharmaceuticals |
Consulting or Advisory Role - FronThera Pharmaceuticals |
| |
|
Employment - ORIC Pharmaceuticals |
Leadership - ORIC Pharmaceuticals |
Stock and Other Ownership Interests - ORIC Pharmaceuticals |
Consulting or Advisory Role - Chimerix; Erasca, Inc |
| |
|
Employment - ORIC Pharmaceuticals |
Stock and Other Ownership Interests - ORIC Pharmaceuticals |
| |
|
Employment - Genentech/Roche; Genentech/Roche (I); ORIC Pharmaceuticals |
Leadership - ORIC Pharmaceuticals |
Stock and Other Ownership Interests - ORIC Pharmaceuticals; Roche; Roche (I) |
Patents, Royalties, Other Intellectual Property - ORIC Pharmaceuticals (Inst) |